Results 11 to 20 of about 12,867 (193)

Effect of Cystamine on Sperm and Antioxidant Parameters of Ram Semen Stored at 4 °C for 50 Hours [PDF]

Archives of Razi Institute, 2021
Physical and chemical changes caused by oxidative stress in the spermatozoa membrane can reduce spermatozoa function and even lead to death. Cystamine (NH2-CH2-CH2-SH, β-mercaptoethylamine) is a natural substance that modulates the endocrine and ...
J Jumintono, S Alkubaisy, D Yánez Silva, K Singh, A Turki Jalil, S Mutia Syarifah, Y Fakri Mustafa, I Mikolaychik, L Morozova, M Derkho   +9 more
doaj   +3 more sources

Enteric-Coated Cysteamine Bitartrate in Cystinosis Patients

Pharmaceutics, 2023
Cystinosis is a severe inherited metabolic storage disease caused by the lysosomal accumulation of cystine. Lifelong therapy with the drug cysteamine bitartrate is necessary. Cysteamine cleaves intralysosomal cystine, and thereafter, it can exit from the
Sabrina Klank, Christina van Stein, Marianne Grüneberg, Chris Ottolenghi, Kerstin K. Rauwolf, Jürgen Grebe, Janine Reunert, Erik Harms, Thorsten Marquardt   +8 more
doaj   +1 more source

Cysteamine affects skeletal development and impairs motor behavior in zebrafish

Frontiers in Pharmacology, 2022
Cysteamine is a kind of feed additive commonly used in agricultural production. It is also the only targeted agent for the treatment of cystinosis, and there are some side effects in clinical applications. However, the potential skeletal toxicity remains
Chao Chen, Chao Chen, Yongliang Zheng, Yongliang Zheng, Xue Li, Xue Li, Li Zhang, Li Zhang, Kangyu Liu, Kangyu Liu, Sujie Sun, Sujie Sun, Zilin Zhong, Zilin Zhong, Hongmei Hu, Hongmei Hu, Fasheng Liu, Guanghua Xiong, Xinjun Liao, Huiqiang Lu, Yanlong Bi, Jianjun Chen, Jianjun Chen, Zigang Cao   +23 more
doaj   +1 more source

A comparison of immediate release and delayed release cysteamine in 17 patients with nephropathic cystinosis

Orphanet Journal of Rare Diseases, 2021
Background Nephropathic cystinosis is a rare and severe metabolic disease leading to an accumulation of cystine in lysosomes which especially harms kidney function.
Christina van Stein, Sabrina Klank, Marianne Grüneberg, Chris Ottolenghi, Jürgen Grebe, Janine Reunert, Erik Harms, Thorsten Marquardt   +7 more
doaj   +1 more source

Cysteamine suppresses invasion, metastasis and prolongs survival by inhibiting matrix metalloproteinases in a mouse model of human pancreatic cancer. [PDF]

PLoS ONE, 2012
BACKGROUND: Cysteamine, an anti-oxidant aminothiol, is the treatment of choice for nephropathic cystinosis, a rare lysosomal storage disease. Cysteamine is a chemo-sensitization and radioprotection agent and its antitumor effects have been investigated ...
Toshio Fujisawa, Benjamin Rubin, Akiko Suzuki, Prabhudas S Patel, William A Gahl, Bharat H Joshi, Raj K Puri   +6 more
doaj   +1 more source

The cytotoxic effect of cysteamine and its combinations with various endodontic intracanal medications on fibroblast cells: in vitro study

Bulletin of the National Research Centre, 2023
Background This study was established to assess cysteamine’s cytotoxic effect alone and in combination with various intracanal medications on fibroblast cells, because the biocompatibility of intracanal medication is considered one of the main factors ...
Esraa Adel Mohamed Abd Elhameed ElGammal, Abeer Hashem Mahran, Salma Hassan El Ashry, Sara Hossam Fahmy   +3 more
doaj   +1 more source

Mechanisms for the Cytotoxicity of Cysteamine [PDF]

Toxicological Sciences, 2001
The major aim of this study was to quantitatively assess the contribution of H2O2 generation to the cytotoxicity induced by cysteamine. Cysteamine produces H2O2 at levels that correlate with its toxicity between 23 and 160 microM. A maximum of 6.9 microM H2O2 is generated by 625 microM cysteamine.
David A. Lawrence, Thomas M. Jeitner
openaire   +3 more sources

Cysteamine Decreases Low‐Density Lipoprotein Oxidation, Causes Regression of Atherosclerosis, and Improves Liver and Muscle Function in Low‐Density Lipoprotein Receptor–Deficient Mice

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021
Background We have shown previously that low‐density lipoprotein (LDL) can be oxidized in the lysosomes of macrophages, that this oxidation can be inhibited by cysteamine, an antioxidant that accumulates in lysosomes, and that this drug decreases ...
Feroz Ahmad, Robert D. Mitchell, Tom Houben, Angela Palo, Tulasi Yadati, Andrew J. Parnell, Ketan Patel, Ronit Shiri‐Sverdlov, David S. Leake   +8 more
doaj   +1 more source

A new proof of evidence of cysteamine quantification for therapeutic drug monitoring in patients with cystinosis

Orphanet Journal of Rare Diseases, 2022
Background To date, measurement of intracellular cystine is used for the therapeutic monitoring of patients affected by cystinosis in treatment with cysteamine.
Martina Franzin, Silvia Rossetto, Rachele Ruoso, Rossella Del Savio, Gabriele Stocco, Giuliana Decorti, Riccardo Addobbati   +6 more
doaj   +1 more source

Challenges for cysteamine stabilization, quantification, and biological effects improvement

Journal of Pharmaceutical Analysis, 2020
The aminothiol cysteamine, derived from coenzyme A degradation in mammalian cells, presents several biological applications. However, the bitter taste and sickening odor, chemical instability, hygroscopicity, and poor pharmacokinetic profile of ...
Carla Atallah, Catherine Charcosset, Hélène Greige-Gerges   +2 more
doaj   +1 more source